Ming Hsieh is Chairman of our Board of Directors and Chief Executive Officer. Prior to founding Fulgent, Mr. Hsieh served as Chief Executive Officer, President and Chairman of the board of directors of Cogent, Inc., or Cogent, a biometric identification services and products company he co-founded in 1990, which was acquired by 3M in 2010. Prior to his tenure at Cogent, Mr. Hsieh founded and served as Vice President of AMAX Technology from 1987 to 1990. Mr. Hsieh currently serves on the board of directors of Fortinet, Inc., a network security company traded on the NASDAQ Global Select Market under the symbol “FTNT.” Mr. Hsieh received a B.S.E.E. from USC in 1983 and an M.S.E.E. from USC in 1984, as well as honorary doctoral degrees from USC in 2010 and the University of West Virginia in 2011. Mr. Hsieh has served as a trustee at USC since 2007 and at Fudan University in China since 2011. In 2015, Mr. Hsieh was elected to the National Academy of Engineering. Mr. Hsieh was selected to serve on our board of directors based on his extensive management experience, his knowledge of our business, culture and operations as our founder, his engineering expertise and his service for and leadership of our company since inception.

Paul Kim has served as Fulgent Chief Financial Officer since 2016. Prior to his service for us, Mr. Kim served as Chief Financial Officer of Cogent, a publicly traded biometric identification services and product company from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, or JNI, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from 1999 to 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From 1996 to 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences, Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.

Hanlin (Harry) Gao, M.D., Ph.D., D.A.B.M.G., F.A.C.M.G. is a founder of our genetic testing business, is our Lab Director and Chief Scientific Officer. Dr. Gao’s prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope. Dr. Gao received a M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990, respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP.

James Xie, a co-founder of Fulgent Genetics, Inc., is our President and Chief Operating Officer. Prior to joining Fulgent, Mr. Xie served as the Senior Vice President of Cogent Inc., a publicly traded biometric identification service and product company from 1996 until 2011. As Chief Operating Officer of Fulgent, Mr. Xie is responsible for managing all global operations, product vision and product engineering. He is focused on unifying all departments to maximize efficiency, drive sustainable growth and inspire continuous innovation.

He received his B.A. in Engineering from Chongqing University in 1987, and has both an M.S. in Industrial Engineering and an M.S. in Computer Science from the University of New South Wales in 1992.  

In his free time, he also is a flight instructor for single-engine, multi-engine, and instrument airplanes. He holds a Commercial Pilot’s License (CPL) and Airline Transport Pilot’s License (ATPL).

Brandon Perthuis joined Fulgent in 2017 and has served as Chief Commercial Officer since 2020. Prior to his service for us, Mr. Perthuis served as Vice President of Sales and Marketing of the Medical Genetics Laboratory at Baylor College of Medicine from 2009 to 2015. In 2015, Mr. Perthuis led the efforts to spin out the laboratory and form the new Baylor Genetics, LLC joint venture with Miraca Sciences, a transaction valued at approximately $300M. Mr. Perthuis was Vice President of the joint venture from 2015 to 2017 and helped develop a new operating model and go to market strategy for this joint venture. Prior to Baylor College of Medicine and Baylor Genetics, he had sales leadership roles at PerkinElmer and Spectral Genomics. Mr. Perthuis’ career has been at the forefront of genetic testing since 2003, leading the commercialization efforts for, among other things, microarray testing, exome sequencing and mitochondrial diagnostics. Mr. Perthuis holds a Bachelor of Science Degree in Biomedical Science from Texas A&M University in College Station, Texas.

 

Dr. Lawrence Weiss is our Chief Medical Officer. Dr. Weiss brings extensive experience in medical and scientific leadership to Fulgent Genetics. Most recently, he was Chief Medical Officer at NeoGenomics where he oversaw the medical and the research and development teams. Prior to NeoGenomics, Dr. Weiss served as Laboratory Director for Clarient Diagnostic Services and as Chairman of the Department of Pathology and Director of Laboratories for City of Hope National Medical Center. Dr. Weiss received his BS summa cum laude and MD summa cum laude from the University of Maryland. He completed a residency in Anatomic Pathology at the Brigham and Women’s Hospital and a fellowship in Surgical Pathology at Stanford University Medical Center. He was previously an Assistant Professor of Pathology at Stanford and President of the Medical Staff and Chairman of Pathology at the City of Hope. He is the author of over 500 papers and book chapters, and has authored or co-authored over a dozen books, including an AFIP Lymph Node Fascicle, Applied Immunohistochemistry, Lymph Nodes, and Knowles’ Hematopathology. His laboratory discovered the first molecular evidence linking the Epstein-Barr virus with Hodgkin Lymphoma. He has won numerous awards, including the Benjamin Castleman, Arthur Purdy Stout, and the United States-Canadian Academy of Pathology Young Investigator Award, and has delivered more than 250 national and international talks in Pathology, including several named lectureships. He has been on the editorial board of over a dozen scientific journals and is a past President of the Los Angeles Society of Pathologists. Dr. Weiss’s diagnostic interests lie in lymph node pathology, immunohistochemistry, solid tumor pathology, and adrenal pathology.

Dr. Ray Yin, co-founder of Fulgent Therapeutics (later split into Fulgent Genetics and Fulgent Pharma), is the president and CSO of Fulgent Pharma. Dr. Yin previously worked at the US Army Research Laboratory managing its nanobiotechnology for chemical and biological defense program, as well as serving as a scientific advisor on various DoD/Joint Service/DARPA/NATO programs and committees. Dr. Yin is a world class expert, a prolific inventor, and an accomplished entrepreneur in the nanobiotechnology area receiving a variety of US and international patents and awards. Some of the major awards include three consecutive US Army R&D Achievement Awards, an AAPS Annual Award, and a National Tibbetts Award. As the Principal Investigator, Dr. Yin successfully led the development of a number of nanotechnology-based products from concept creation to final product fielding/commercialization. These include the first nanotechnology-based rapid multiplexed biological agent detection system currently fielded by DoD, the commercialization of an FDA EUA authorized COVID-19 antigen rapid test supported under the NIH/RADx initiative, as well as a 1st -in-class nano-drug delivery system that has achieved US FDA DMF status with a clinical stage drug currently under development. Dr. Yin received his Ph.D. in chemistry from the University of Southern California.

Natalie oversees Fulgent’s legal operations including legal, privacy, and healthcare regulatory matters. Prior to joining Fulgent, she spent over 15 years at premier AmLaw100 firms, Mintz Levin and Latham & Watkins, and clerked for a federal judge in the Southern District of California. Her expertise includes business litigation, privacy and cybersecurity, healthcare class actions, securities litigation, and regulatory matters. She is a published book author and an award-winning trial lawyer, including such prominent awards as “Lawyer of the Year,” “Best Lawyers in America,” “Super Lawyers,” and IBA’s “Outstanding Young Lawyer of the Year”. She is a graduate of the Trial Lawyers College; a Certified Information Privacy Professional (CIPP/US; CIPP/E); and a Certified Information Privacy Manager (CIPM) with the IAPP. In 2022, she had earned a highly prestigious designation of a Privacy Law Specialist (PLS) with the American Bar Association and the International Association of Privacy Professionals. Natalie holds a B.A. from the University of Southern Mississippi, an M.A. from Tulane University, and a J.D. from Duke University School of Law.